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Objective. Midkine (MK) is a heparin-binding growth factor that is overexpressed in various human cancers. The aim of this
study was to investigate the expression of MK in ameloblastomas and correlate the results with clinicopathologic parameters.
Study Design. Cases of ameloblastoma seen between 1999 and 2010 were identified. Clinical information was collected regarding
age, gender, race, and location of tumor. Cases were classified as solid/multicystic, unicystic, and peripheral. The expression of
midkine was assessed using immunohistochemistry. A significant difference was considered present at P  0.05.
Results. A total of 34 cases of ameloblastoma and 4 cases of ameloblastic carcinomas were identified. MK was expressed in
67% of lesions (23.5% weak expression; 14.7% moderate expression; 29.4% strong expression). A significant difference was
seen between solid/multicystic and unicystic lesions.
Conclusions. MK is expressed in the majority of ameloblastomas, suggesting a role of the protein in the tumor’s development,
progression, and behavior. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:497-502)Ameloblastoma is a locally aggressive, benign neo-
plasm with a tendency to invade the surrounding tissues
and characterized by a relatively high risk of recur-
rence.1 It is the most frequent clinically significant
odontogenic tumor identified, with studies from differ-
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http://dx.doi.org/10.1016/j.oooo.2012.06.013ent regions of the world indicating that it accounts for
9% to 88% of all odontogenic neoplasms. In the United
States, ameloblastomas represent nearly 11% of all
odontogenic neoplasms.2
Ameloblastomas are clinically and radiographically
divided into solid/multicystic, unicystic, and peripheral.
Solid/multicystic is the most common and aggressive
type.3 Unicystic and peripheral ameloblastomas repre-
sent less common lesions, with reports indicating a less
aggressive behavior.4,5 Microscopically, ameloblasto-
mas show a wide variety of patterns, without major
influence on the behavior of the tumor.5 The treatment
for ameloblastoma ranges from conservative enucle-
ation to radical resection of the jaw, depending on the
size, location, and subtype. The recurrence rate for
solid/multicystic tumors after conservative treatment
varies from 36% to 93% and from 8% to 21% with
aggressive radical treatment.6
Midkine (MK) is a 13-kDa heparin-binding growth
factor7,8 that was found as the product of a retinoic acid
gene located at chromosome 11p11.2.9 MK is highly
Statement of Clinical Relevance
Our findings show that immunohistochemical anal-
ysis of midkine may be useful in evaluating cases in
which the hematoxylin–eosin characteristics are not
easily recognizable as ameloblastomas and also
demonstrate that the protein could possibly serve as
a molecular-based therapeutic target for the treat-
ment of ameloblastomas.497
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genesis and is involved in lung, kidney, bone, and tooth
development.10 Although its expression is highly re-
stricted in the normal tissues of adults, studies have
demonstrated that this protein is overexpressed in var-
ious human cancers.7,8 Indeed, this protein has various
biological activities that can contribute to tumor pro-
gression, including positive effects on angiogenesis and
cell proliferation, as well as antiapoptotic proper-
ties.10-14
Previous studies suggest that MK may be involved in
the development of ameloblastomas15,16 and that the
protein may give a growth advantage to ameloblasts
through the upregulation of the MAPK and Akt path-
ways.15 However, these studies did not address whether
levels of MK expression correlated with clinical and
histopathologic patterns. Because we have previously
shown that the PTEN/Akt/mTOR pathway is altered in
ameloblastomas,17 the purpose of this study was to
immunohistochemically investigate the expression pro-
file of MK in the tumor and to correlate the results with
clinical and histologic parameters.
MATERIAL AND METHODS
Patients diagnosed with ameloblastoma and ameloblas-
tic carcinoma of the maxilla, mandible, or gingiva and
treated by primary tumor resection at the University of
Maryland, Federal University of Goiás, and Chulalong-
korn University between 1999 and 2010 were identi-
fied. Clinical records for the ameloblastoma patients
were reviewed and information was gathered regarding
age, gender, race, and location of the tumor. The mi-
croscopic features were reviewed based on a single
5-m hematoxylin and eosin–stained section for each
case. Based on clinical, radiographic, and pathologic
criteria, ameloblastoma cases were classified as solid/
multicystic, unicystic, or peripheral. A total of 15 den-
tal follicles were used as a control. Internal Review
Board exemption was received from the University of
Maryland, Baltimore.
Paraffin-embedded tissues were sectioned (3 m)
and serially collected on glass slides coated with 2%
3-aminopropyltriethoxysilane (Sigma–Aldrich, St. Louis,
MO). Following deparaffinization by immersion in xy-
lene, the sections were immersed in alcohol and incu-
bated with 3% hydrogen peroxide for 40 minutes. For
antigen retrieval, the sections were immersed in citrate
buffer (pH 6.0) for 20 minutes. Subsequently, the sec-
tions were incubated for 20 minutes with 3% normal
goat serum at room temperature. The slides were incu-
bated at 4°C overnight with monoclonal mouse antihu-
man MK primary antibody (clone A-9, Santa Cruz
Biotechnology, Santa Cruz, CA) at 1:50. After being
washed with Tris-buffered saline, the sections werelabeled with streptavidin–biotin (LSAB kit K0492;
Dako, Carpinteria, CA) and then incubated with 3,3=-
diaminobenzidine (K3468, Dako) for 2 to 5 minutes at
room temperature. Finally, the sections were stained
with Mayer’s hematoxylin and covered. Negative con-
trols were obtained by omission of the primary anti-
bodies, which were substituted with 1% phosphate-
buffered saline/bovine serum albumin.
Two independent individuals with advanced educa-
tion in oral pathology reviewed the immunostains. Im-
munohistochemical reactivity for all stains were graded
in a semiquantitative manner according to the percent-
age of positive tumor cells: (0) 0%, (1) 20%, (2) 20%
to 50%, and (3) 50%, as well as the intensity of
staining: (—) no staining, (w) weak, (m) moderate, or
(s) strong. The values for the quality (w  1, m  2,
s  3) and quantity (0–3) of staining were added to
give a single number for each tumor, which was used in
the final evaluation. Staining was considered weak if
the total score was 3, moderate if the score was
between 3 and 5 points, and strong if the total score was
6 points.
Correlation between MK expression and gender, age
(50 vs 50 years), race, histologic type, and pattern
of staining was performed. Last, we also reviewed the
staining results for PTEN, p-PTEN, Akt, p-thr Akt,
p-ser Akt, Erk, and p-S6K from our previous study17 to
search for a correlation with the MK staining findings.
For all measurements where applicable, a Student t test
was used to assess the statistical significance, along
with standard error. A significant difference was con-
sidered present at P  0.05.
RESULTS
A total of 34 cases of ameloblastoma and 4 cases of
ameloblastic carcinomas were identified. For amelo-
blastomas, gender equated to 22 males (66%) and 11
females (34%) or 2:1, respectively, with a mean age of
48.8 years (range 16-86). Gender information was un-
available in 1 case. There were 20 white (58%), 13
black (38%), and 1 Asian (2%) patient. Thirty lesions
were located in the mandible, 2 in the maxilla, and 1
involving the gingiva (peripherally). Based on clinico-
pathologic criteria, the 34 ameloblastomas were classi-
fied as solid/multicystic (24), unicystic (9), and periph-
eral (1). The average age of patients with solid/
multicystic ameloblastomas was 54.8 years (range 22-
86), with a 2.8:1 male-to-female ratio and a 1.1:1
white-to-black ratio. Most of these cases (22) were in
the mandible (91%), with only 2 (19%) in the maxilla.
Further, most solid/multicystic ameloblastomas ap-
peared histologically with a follicular pattern (50%),
followed by a plexiform configuration (34%), mixed
follicular/plexiform pattern (8%), and acanthomatous
OOOO ORIGINAL ARTICLE
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ameloblastomas was 36.7 years (range 11-70), with a
1.25:1 female-to-male ratio and a 3.5:1 white-to-black
ratio. Eight lesions were found in the mandible and 1 in
the maxilla. Figure 1 shows the radiographic and his-
topathologic aspects of a select case of unicystic amelo-
blastoma. The single case of peripheral ameloblastoma
affected the gingiva of a 48-year-old white male. His-
tologically, the peripheral lesion presented with a fol-
licular pattern (Table I). Finally, the average age of
patients with ameloblastic carcinomas was 52.7 years
(range 38-71), with a 3:1 male-to-female ratio. One
lesion affected a white individual, 2 were seen in black
patients, and race was unavailable in 1 case. All 4
ameloblastic carcinomas were found in the mandible.
Follow-up information was not available for the cases.
MK was expressed in 67% (23 of 34 cases) of the
ameloblastomas (weak expression in 23.5%; moderate
expression in 14.7%; strong expression in 29.4%). The
overall staining score was 3.05 when considering all
lesions (positive and negative) and 4.52 when consid-
ering positive lesions only. Figure 2 shows representa-
Fig. 1. (a) Radiographic and (b) histopathologic aspects of a
unicystic ameloblastoma.tive images of MK immunohistochemistry. Regardingdental follicles, 6 of 15 showed MK positivity (1 case
strong, 3 cases moderate, and 1 case weak expression),
with an average staining score of 1.5. The average MK
staining score was statistically higher in ameloblasto-
mas than in dental follicles (P  0.03). When stratified
according to histologic subtype, solid/multicystic tu-
mors showed an average score of 3.96, compared with
a score of 1.00 for unicystic lesions (P  0.001). The
most common staining pattern was in the stellate re-
ticulum–like cells only (56%), followed by staining
observed in both the stellate reticulum–like cells and
the peripheral columnar ameloblast–like cells (39% of
cases; Figure 2). In 1 case, only the columnar amelo-
blast–like cells stained. Strong MK expression was
found in 2 of 4 cases of ameloblastic carcinomas,
whereas 1 case showed moderate staining (average
score of 4.3). Figure 3 shows representative images of
MK expression in a dental follicle, solid/multicystic
ameloblastoma, unicystic ameloblastoma, and amelo-
blastic carcinoma. No significant differences in MK
scores were observed in relation to age, gender, race, or
pattern of staining.
Of the 34 cases stained for MK, 15 had been utilized
in our previous study17 where we assessed the expres-
sion of other proteins also involved in the PI3K/Akt
pathway, namely PTEN, p-PTEN, Akt, p-thr Akt, p-ser
Akt, Erk, and p-S6K. The average staining score for
these proteins was 2.46, 0.60, 2.60, 2.94, 2.00, 2.13,
and 3.13, respectively. In the ameloblastomas that were
positive to MK (12 of 15), total PTEN was present in
75% of cases, whereas p-PTEN was present in only
25%. Total AKT was upregulated in 66.7% of cases of
ameloblastoma, whereas p-thr AKT and p-ser AKT
were overexpressed in 100% and 66.7% of cases, re-
spectively. Active p-S6K expression (the terminal ef-
fector of the Akt/mTor pathway) was upregulated in
91.6% cases. Finally, ERK, a signaling molecule that
cross-talks with AKT and can also activate mTOR and
p-S6K, was also overexpressed in 66.7% of cases.
DISCUSSION
MK is a heparin-binding cytokine that promotes
growth, survival, migration, and other activities of tar-
get cells.18 To date, only 2 studies have assessed the
expression of MK in ameloblastomas, an aggressive
neoplasm that exhibits the disruption of various molec-
ular pathways involved with cell proliferation and
survival, including the sonic hedgehog and PI3K/Akt/
mTor pathways.19 Sandra et al.15 examined, immuno-
histochemically, the expression of MK in 37 amelo-
blastomas. The protein was expressed in 70% of cases,
mostly in the outer layer of ameloblast-like cells. Later,
Fujita et al.16 examined the expression of MK in vari-
ous human odontogenic tumors, including 55 amelo-
in 1 c
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30 of 55 (54.5%) ameloblastomas, mostly confined to
the columnar ameloblast–like cell cytoplasm. In our
study, we found that 67% of the ameloblastomas
stained for MK, a finding in between that of previous
reports. A more significant difference was observed in
the pattern of staining in relation to previous studies.
Whereas previous studies showed that MK was ex-
pressed in the ameloblast-like cells, most of our cases
Table I. Demographic data*
Age (years) Gender Race
Range Average Male Female White Black Asian M
M/S (24) 22-86 54.8 17 6 12 11 1
U (9) 11-70 36.7 4 5 7 2 —
P (1) — 48 1 — 1 — —
AC (4) 38-71 52.7 3 1 1 2
AC, ameloblastic carcinoma; M/S, multicystic/solid; P, peripheral; U
*Gender was unavailable in 1 case of M/S and race was unavailable
Fig. 2. Strong expression of midkine (brown stain) by stellate
reticulum–like cells and peripheral columnar ameloblast–like
cells in the solid/multicystic ameloblastoma. (b) A close-up
view of (a). Immunohistochemical staining; original magni-
fication: 200 (a) and 400 (b).showed staining of the stellate reticulum–like cells onlyor combined staining of both stellate reticulum–like and
ameloblast-like cells. Only 1 of our cases showed stain-
ing of ameloblast-like cells alone. Importantly, previ-
ous studies did not assess whether a correlation existed
between MK expression and clinicopathologic param-
eters. Thus, we also sought to investigate whether MK
expression correlated with clinical and pathologic as-
pects of ameloblastomas and to determine whether the
protein could be involved with distinct clinical behav-
ior. Here, we observed that MK expression was signif-
icantly stronger in solid/multicystic lesions compared
with unicystic tumors, suggesting that the protein may
be involved in more aggressive behavior. Indeed, other
studies have indicated that certain signaling pathways,
such as the Notch pathway, may play roles in the
acquisition of different ameloblastoma phenotypes.20 A
limitation of our study was the lack of follow-up data,
which prevented us from investigating the correlation
between MK expression and tumor biological aggres-
siveness.
The protein (serine/threonine) kinase Akt integrates a
plethora of extracellular signals that lead to cell prolif-
eration and survival.21 Genetic alterations leading to an
overactivation of the Akt pathway are frequent in a
wide variety of human cancers.22,23 Indeed, the Akt
pathway is the second most frequently mutated path-
way in cancer, after mutations of the tumor suppressor
protein p53.21 In this context, in vitro studies show that
MK induces the phosphorylation (at Ser473 and
Thr308) and activation of Akt and that upon pretreat-
ment of cells with LY294002 (a PI3K/Akt inhibitor),
MK-stimulated phosphorylation of Akt and MK-stim-
ulated growth of cells was inhibited.15 Fifteen of the 27
samples in our studies had been employed in a previous
study where we analyzed the Akt pathway in amelo-
blastomas.17 In the current study, we found that all
MK-positive samples also showed activation of Akt at
Thr308, whereas 66.7% showed upregulation of p-Akt
at Ser473, in agreement with previous studies. How-
ever, we also observed that 25% of the samples lacked
PTEN and 75% lacked p-PTEN, which could also
account for the increased Akt activation seen in our
Location Histologic typing
Maxilla Gingiva Follicular Plexiform Mixed Acanthomatous
2 — 12 8 2 2
1 — — — — —
— 1 1 — — —
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AKT pathway is mTOR, which is critical for cell pro-
liferation, survival, and tumorigenesis.24 In our study,
p-S6K, which is the terminal effector of the mTOR
pathway, was overexpressed in 86.6% of cases that
were positive for MK, suggesting that the latter partic-
ipates in the growth and progression of ameloblastomas
through the Akt/mTOR pathway. Alternatively, MK
may activate the mTOR pathway through Akt-indepen-
dent pathways; indeed, we observed that 66.7% of the
MK-positive samples also showed activation of Erk, a
signaling molecule that can also activate p-S6K and
mTOR. Together, these results indicate that MK may
be an important therapeutic target in ameloblastomas,
with the potential to block 2 important downstream
pathways that participate in cell proliferation and sur-
vival (Akt/mTOR and Erk/mTOR).
Ameloblastic carcinoma is a rare, malignant, odon-
togenic tumor that arises de novo or from a preexisting
ameloblastoma.25 The microscopic features favoring
the malignant transformation include the presence of
sheets, islands, or trabeculae of epithelium; the absence
of stellate reticulum–like structures; and round-to-spin-
dled epithelial cells with little or no differentiation
toward the columnar cell morphology of ameloblas-
toma.26 Clinically, Yoon et al.25 found that ameloblas-
tic carcinoma showed a much higher mean age, a
higher rate of occurrence in men, and a relatively
higher proportion of maxillary lesions compared with
Fig. 3. Representative expression of midkine (brown stain)
ameloblastoma (c), and ameloblastic carcinoma (d). Immunoameloblastoma. Similarly, our 4 cases also showed highmean age and were more frequent in men; however, all
cases were seen in the mandible. Because of its rarity,
there are few immunoprofile studies of ameloblastic
carcinoma and few comparative studies of ameloblastic
carcinoma and ameloblastoma.25 Thus, in the current
study we also stained ameloblastic carcinomas with
MK and found that three quarters of the tumors (75%)
were moderately to strongly positive to the protein,
with scores higher than that seen for ameloblastomas.
Our results are in agreement with the study by Fujita et
al.,16 who found that two thirds (66%) of ameloblastic
carcinomas were positive to MK (compared with
54.5% of ameloblastomas).
In conclusion, our results show that MK is expressed in
the majority of ameloblastomas, particularly solid/multi-
cystic lesions, suggesting a role of the protein in the
development, progression, and behavior of the tumor. The
immunohistochemical analysis of MK may be useful in
evaluating cases where the hematoxylin–eosin character-
istics are not easily recognizable as ameloblastomas. In
addition, MK may represent a molecular-based target for
the treatment of ameloblastomas. Further studies are war-
ranted to confirm our observations.
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